Boyle Scott N

Chief Business OfficerC4 Therapeutics, Inc. (CCCC) · full profile →Form 4 · filed Feb 18, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$4K
Net Open-Market Flow
-$4K
Transactions
6
5 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 18, 2025Sell(S)669$3.15$2K108K
Feb 14, 2025Grant(A)57K$0111K
Feb 14, 2025Sell(S)490$3.15$2K111K
Feb 14, 2025Tax withholding(F)2K$3.18$8K108K
Feb 13, 2025Tax withholding(F)2K$3.20$6K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 14, 2025Grant(A)85K$085K

Transaction Codes

S
Open-market sale
A
Grant / award
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001662579-25-000019) within minutes of acceptance. Every field above traces to the original document. Verify it directly: